Celldex/$CLDX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Celldex
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
- Ticker
- $CLDX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 198
- Headquarters
- Hampton, United States
- Website
- www.celldex.com
Celldex Metrics
BasicAdvanced
$2.2B
-
-$4.33
0.84
-
Price and volume
Market cap
$2.2B
Beta
0.84
52-week high
$45.14
52-week low
$22.10
Average daily volume
1.4M
Financial strength
Current ratio
11.821
Quick ratio
11.705
Long term debt to equity
0.005
Total debt to equity
0.007
Profitability
EBITDA (TTM)
-322.432
Gross margin (TTM)
-176,360.13%
Net profit margin (TTM)
-190,220.89%
Operating margin (TTM)
-206,220.25%
Management effectiveness
Return on assets (TTM)
-27.62%
Return on equity (TTM)
-43.88%
Valuation
Price to revenue (TTM)
12,410.009
Price to book
3.11
Price to tangible book (TTM)
3.23
Price to free cash flow (TTM)
-8.097
Free cash flow yield (TTM)
-12.35%
Free cash flow per share (TTM)
-3.491
Growth
Revenue change (TTM)
-97.27%
Earnings per share change (TTM)
44.10%
3-year revenue growth (CAGR)
-63.52%
10-year revenue growth (CAGR)
-29.89%
3-year earnings per share growth (CAGR)
21.67%
10-year earnings per share growth (CAGR)
-14.16%
What the Analysts think about Celldex
Analyst ratings (Buy, Hold, Sell) for Celldex stock.
Analyst projections of the future price of Celldex stock.
Bulls say / Bears say
Barzolvolimab cleared the main and key secondary goals in both Phase 3 CSU trials, with complete responses in about 42%–46% of treated patients at week 12 versus 9%–13% on placebo. The results establish a strong late-stage efficacy case in a large, difficult-to-treat population. (Reuters)
Earlier CSU results showed that benefits may persist after treatment stops: up to 64% of patients with angioedema remained swelling-free seven months after dosing ended. If confirmed in further follow-up, this durability could reduce the burden of continuous treatment. (GlobeNewswire)
Barzolvolimab also has potential beyond CSU: its Phase 2 study in cold urticaria and symptomatic dermographism met all primary and secondary endpoints, and a Phase 3 study is under way. Success there would give Celldex another route to expand the drug’s commercial opportunity. (GlobeNewswire)
The Phase 3 results brought potential safety hurdles: two cases of anaphylaxis were reported in treated patients, alongside frequent hair-colour changes and neutropenia. These effects could affect regulator warnings, patient acceptance and prescribing. (BioPharma Dive)
Barzolvolimab failed to meet the primary or key secondary endpoints in a Phase 2 prurigo nodularis study despite clear evidence of mast-cell depletion. The miss shows the drug’s mechanism may not work across all targeted diseases and weakens the case for broader pipeline potential. (Fierce Biotech)
Celldex remains loss-making and may need further financing: it used $123 million of operating cash in the first half of 2026 and raised $323.8 million net through a share issuance. That financing supports development, but further equity raises could dilute existing shareholders. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
Celldex Financial Performance
Revenues and expenses
Celldex Earnings Performance
Company profitability
Upcoming events
No upcoming events
Celldex News
AllArticlesVideos
Funds containing Celldex
Fund name | Fund size | $CLDX weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.08% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.08% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.06% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.06% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.